Advertisement
Advertisement
U.S. Markets open in 1 hr 55 mins
Advertisement
Advertisement
Advertisement
Advertisement

Adicet Bio, Inc. (ACET)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
12.99+1.06 (+8.89%)
At close: 04:00PM EST
12.99 0.00 (0.00%)
After hours: 04:53PM EST
Advertisement

Adicet Bio, Inc.

500 Boylston Street
13th Floor
Boston, MA 02116
United States
857 315 5528
https://www.adicetbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees81

Key Executives

NameTitlePayExercisedYear Born
Mr. Chen Schor BA, CPA, CPA, M.B.A., MBACEO, Pres & Director750.08kN/A1972
Dr. Aya Jakobovits Ph.D.Founder & Independent Director12.83kN/A1953
Dr. Francesco Galimi M.D., Ph.D.Chief Medical Officer & Sr. VP706.18kN/A1968
Mr. Brian Nicholas HarveyChief Financial OfficerN/AN/A1961
Dr. Donald HealeyChief Technology OfficerN/AN/A1962
Dr. Blake Aftab Ph.D.Sr. VP & Chief Scientific OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors, including hepatocellular carcinoma, gastric cancer, and squamous cell carcinoma of the lung. The company is based in Boston, Massachusetts.

Corporate Governance

Adicet Bio, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 10. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement